204 related articles for article (PubMed ID: 31428104)
1. Polymorphism in the
Daniel C; Dewitte A; Poiret S; Marceau M; Simonet M; Marceau L; Descombes G; Boutillier D; Bennaceur N; Bontemps-Gallo S; Lemaître N; Sebbane F
Front Immunol; 2019; 10():1830. PubMed ID: 31428104
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the protective immune response to Yersinia pseudotuberculosis infection in mice vaccinated with an LcrV-secreting strain of Lactococcus lactis.
Daniel C; Titecat M; Poiret S; Cayet D; Boutillier D; Simonet M; Sirard JC; Lemaître N; Sebbane F
Vaccine; 2016 Nov; 34(47):5762-5767. PubMed ID: 27742220
[TBL] [Abstract][Full Text] [Related]
3. Oral vaccination with LcrV from Yersinia pestis KIM delivered by live attenuated Salmonella enterica serovar Typhimurium elicits a protective immune response against challenge with Yersinia pseudotuberculosis and Yersinia enterocolitica.
Branger CG; Torres-Escobar A; Sun W; Perry R; Fetherston J; Roland KL; Curtiss R
Vaccine; 2009 Aug; 27(39):5363-70. PubMed ID: 19596407
[TBL] [Abstract][Full Text] [Related]
4. Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV.
Daniel C; Sebbane F; Poiret S; Goudercourt D; Dewulf J; Mullet C; Simonet M; Pot B
Vaccine; 2009 Feb; 27(8):1141-4. PubMed ID: 19135495
[TBL] [Abstract][Full Text] [Related]
5. Vaccine Potential of a Recombinant Bivalent Fusion Protein LcrV-HSP70 Against Plague and Yersiniosis.
Gupta A; Narayan B; Kumar S; Verma SK
Front Immunol; 2020; 11():988. PubMed ID: 32595634
[TBL] [Abstract][Full Text] [Related]
6. A Recombinant Attenuated
Singh AK; Curtiss R; Sun W
Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31331960
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in the lcrV gene of Yersinia enterocolitica and their effect on plague protective immunity.
Miller NC; Quenee LE; Elli D; Ciletti NA; Schneewind O
Infect Immun; 2012 Apr; 80(4):1572-82. PubMed ID: 22252870
[TBL] [Abstract][Full Text] [Related]
8. Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.
Wang S; Goguen JD; Li F; Lu S
Vaccine; 2011 Sep; 29(39):6802-9. PubMed ID: 21199697
[TBL] [Abstract][Full Text] [Related]
9. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
[TBL] [Abstract][Full Text] [Related]
10. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
[TBL] [Abstract][Full Text] [Related]
11. LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.
Sun W; Sanapala S; Henderson JC; Sam S; Olinzock J; Trent MS; Curtiss R
Infect Immun; 2014 Oct; 82(10):4390-404. PubMed ID: 25114109
[TBL] [Abstract][Full Text] [Related]
12. Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine.
Demeure CE; Derbise A; Guillas C; Gerke C; Cauchemez S; Carniel E; Pizarro-Cerdá J
Vaccine; 2019 Jan; 37(1):123-129. PubMed ID: 30467064
[TBL] [Abstract][Full Text] [Related]
13. Oral vaccination with live attenuated Yersinia pseudotuberculosis strains delivering a FliC180-LcrV fusion antigen confers protection against pulmonary Y. Pestis infection.
Singh AK; Wang X; Sun W
Vaccine; 2020 May; 38(21):3720-3728. PubMed ID: 32278523
[TBL] [Abstract][Full Text] [Related]
14. Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis.
Gallagher TB; Mellado-Sanchez G; Jorgensen AL; Moore S; Nataro JP; Pasetti MF; Baillie LW
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007644. PubMed ID: 31430284
[TBL] [Abstract][Full Text] [Related]
15. Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague.
Do Y; Koh H; Park CG; Dudziak D; Seo P; Mehandru S; Choi JH; Cheong C; Park S; Perlin DS; Powell BS; Steinman RM
Eur J Immunol; 2010 Oct; 40(10):2791-6. PubMed ID: 20812236
[TBL] [Abstract][Full Text] [Related]
16. HSP70 domain II of Mycobacterium tuberculosis modulates immune response and protective potential of F1 and LcrV antigens of Yersinia pestis in a mouse model.
Batra L; Verma SK; Nagar DP; Saxena N; Pathak P; Pant SC; Tuteja U
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3322. PubMed ID: 25474358
[TBL] [Abstract][Full Text] [Related]
17. Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen.
Roggenkamp A; Geiger AM; Leitritz L; Kessler A; Heesemann J
Infect Immun; 1997 Feb; 65(2):446-51. PubMed ID: 9009295
[TBL] [Abstract][Full Text] [Related]
18. N255 is a key residue for recognition by a monoclonal antibody which protects against Yersinia pestis infection.
Hill J; Leary S; Smither S; Best A; Pettersson J; Forsberg A; Lingard B; Lipka A; Brown KA; Williamson ED; Titball RW
Vaccine; 2009 Nov; 27(50):7073-9. PubMed ID: 19786138
[TBL] [Abstract][Full Text] [Related]
19. Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis.
Philipovskiy AV; Cowan C; Wulff-Strobel CR; Burnett SH; Kerschen EJ; Cohen DA; Kaplan AM; Straley SC
Infect Immun; 2005 Mar; 73(3):1532-42. PubMed ID: 15731051
[TBL] [Abstract][Full Text] [Related]
20. Direct neutralization of type III effector translocation by the variable region of a monoclonal antibody to Yersinia pestis LcrV.
Ivanov MI; Hill J; Bliska JB
Clin Vaccine Immunol; 2014 May; 21(5):667-73. PubMed ID: 24599533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
